Relugolix for oral treatment of uterine leiomyomas: a dose-finding, randomized, controlled trial

BACKGROUND: Uterine leiomyomas are the most common neoplasm affecting women and frequently cause heavy menstrual bleeding and pain. Gonadotropin-releasing hormone (GnRH) receptor antagonists provide fast symptom relief and show promise as a medical (non-surgical) treatment option and as a presurgica...

Descripción completa

Detalles Bibliográficos
Autores principales: Hoshiai, Hiroshi, Seki, Yoshifumi, Kusumoto, Takeru, Kudou, Kentarou, Tanimoto, Masataka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8555132/
https://www.ncbi.nlm.nih.gov/pubmed/34711224
http://dx.doi.org/10.1186/s12905-021-01475-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8555132/
https://www.ncbi.nlm.nih.gov/pubmed/34711224
http://dx.doi.org/10.1186/s12905-021-01475-2

Ejemplares similares